Drugs / Pegteograstim
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT06353581 | Feb 2022 → May 2024 | malignant pancreatic neoplasm | Yonsei University | Unknown | Met primary |
| Phase 2 | NCT02840539 | Oct 2016 → Mar 2021 | mantle cell lymphoma | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02787876 | Oct 2016 → Oct 2018 | childhood malignant neoplasm, neutropenia | Samsung Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04065308 Background | Jan → Dec 2019 | plasma cell myeloma, plasmacytoma | Seoul National University Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegteograstim | “Pegteograstim (Neulapeg®) is a pegylated human recombinant granulocyte colony-stimulating factor with a long half-life (15-80 hours) compared to filgrastim (3-4 hours).” NCT06353581 ↗3“Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle” NCT04065308 ↗ |
| Known as | Neulapeg | “PURPOSE: Pegteograstim (Neulapeg) is a recombinant human granulocyte colony-stimulating factor conjugated with methoxy-maleimide-polyethylene glycol.” PMID 34010932 ↗ Mar 2022 |
| Action | Activate | “Granulocyte colony stimulating factor receptor agonist” CHEMBL4297800 ↗ |
| Modality | Protein / enzyme biologic | “Pegteograstim (Neulapeg) is a recombinant human granulocyte colony-stimulating factor conjugated with methoxy-maleimide-polyethylene glycol.” PMID 34010932 ↗ Mar 2022 |
| Route | Subcutaneous | “Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle” NCT04065308 ↗ |
| Target | CSF3R | “Granulocyte colony stimulating factor receptor agonist” CHEMBL4297800 ↗ |